ECHINOMYCIN (NSC-526417) IN SQUAMOUS-CELL CARCINOMA OF THE CERVIX - A PHASE-II TRIAL OF THE GYNECOLOGIC ONCOLOGY GROUP

被引：23

作者：

MUSS, HB

BLESSING, JA

MALFETANO, J

机构：

[1] ALBANY MED CTR,DEPT OBSTET & GYNECOL,ALBANY,NY

[2] WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT MED,WINSTON SALEM,NC 27103

[3] NEW YORK STATE DEPT HLTH,ROSWELL PK MEM INST,GYNECOL ONCOL GRP,DEPT STAT,BUFFALO,NY 14263

来源：

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 1990年 / 13卷 / 03期

关键词：

D O I：

10.1097/00000421-199006000-00002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Twenty-eight evaluable patients with advanced or recurrent squamous-cell carcinoma of the cervix were treated with 1,500 μg/m2 of echinomycin every 4 weeks. All patients had prior chemotherapy. Two patients had partial responses (7% response, 95% confidence interval for response of 1 to 24%). The major toxicity was nausea and vomiting. Myelosuppression and other toxicity were modest. Echinomycin, at this dose and schedule, displays minimal activity in patients with squamous-cell carcinoma of the cervix who have had prior chemotherapy.

引用

页码：191 / 193

页数：3